1,660 results on '"Schiano, Thomas"'
Search Results
152. High-temperature ex-vessel corium spreading. Part 2: scaling principles for gravity-viscous spreading with slip at the melt–substrate interface
153. S1355 Sepsis in Hospitalizations With Short Bowel Syndrome: A 10-Year Analysis From the National Inpatient Sample Database
154. DCD Hepatitis C Virus–positive Donor Livers Can Achieve Favorable Outcomes With Liver Transplantation and Are Underutilized
155. Liver Transplantation for Alcoholic Hepatitis: A Survey of Liver Transplant Centers
156. A pleasant dilemma to have: to treat the HCV patient on the waiting list or to treat post-liver transplantation?
157. Eliminating transplant tourism in the United States as a means to decrease wait-list mortality of US residents
158. High-risk liver transplant candidates: An ethical proposal on where to draw the line
159. Primary Sclerosing Cholangitis: Detailed Histologic Assessment and Integration Using Bioinformatics Highlights Arterial Fibrointimal Hyperplasia as a Novel Feature
160. Segment 4 and the left lateral segment regeneration pattern after resection of the middle hepatic vein in a living donor right hepatectomy
161. Non-Newtonian spreading simulation of molten nuclear combustible
162. Performance of native and gadoxetate-enhanced liver and spleen T1 mapping for noninvasive diagnosis of clinically significant portal hypertension: preliminary results.
163. Obliterative Portal Venopathy: A Clinical and Histopathological Review
164. Mucosal Addressin Cell Adhesion Molecule (MAdCAM-1) Expression Is Upregulated in the Cirrhotic Liver and Immunolocalises to the Peribiliary Plexus and Lymphoid Aggregates
165. Recurrent Disease Post-Liver Transplantation: Autoimmune Diseases, Hepatitis B and NASH
166. Hepatitis C Post-Liver Transplantation
167. Non-Cirrhotic Portal Hypertension
168. Extensive Health Care Utilization and Costs of an Early Liver Transplantation Program for Alcoholic Hepatitis
169. The utility and complications of plasma administration in cirrhotic patients undergoing minimally invasive procedures
170. The presence of non‐hepatic malignancy and its implication in pursuing liver transplantation
171. Hemophagocytic lymphohistiocytosis occurring after liver transplantation: A case series and review of the literature
172. Corrigendum to “Erythropoietin administration expands regulatory T cells in patients with autoimmune hepatitis” [J. Autoimmun. 119C (2021) 102629]
173. Efficacy and safety of mammalian target of rapamycin inhibitors following intestinal and multivisceral transplantation
174. Evaluation of the fibrosis‐4 index for detection of advanced fibrosis among individuals at risk for intestinal failure–associated liver disease
175. Outcome of COVID‐19 in Patients With Autoimmune Hepatitis: An International Multicenter Study
176. Extrahepatic autoimmune diseases in primary biliary cholangitis : Prevalence and significance for clinical presentation and disease outcome
177. The Management of Hospitalized Patients with Cirrhosis: The Mount Sinai Experience and a Guide for Hospitalists
178. Hemophagocytic syndrome occurring in an adult liver transplant recipient having Still’s disease
179. The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV
180. Regression of Hepatic Fibrosis After Intestinal Transplantation in Total Parenteral Nutrition Liver Disease
181. Comparative Killing Kinetics of Methicillin-Resistant Staphylococcus aureus by Bacitracin or Mupirocin
182. Lamivudine resistance leading to de novo hepatitis B infection in recipients of hepatitis B core antibody positive liver allografts
183. Medication Level Variability Index Predicts Rejection, Possibly Due to Nonadherence, in Adult Liver Transplant Recipients
184. Geographic disparity: the dilemma of lower socioeconomic status, multiple listing, and death on the liver transplant waiting list
185. Hepatitis C Virus Eludes IFN-mediated Antiviral Responses by Producing a Genomic Reservoir Protected in Double-stranded RNA; Ribavirin Blocks this Escape Strategy: 228
186. Early phase 1 clinical trial results of GR-MD-02, a galec-tin-3 inhibitor, in patients having non-alcoholic steato-hepatitis (NASH) with advanced fibrosis: 57
187. Prevention of Hepatitis C Virus (HCV) Recurrence with Peri-Transplant Hepatitis C Immune Globulin Combined with Pre-Transplant (Pre-LT) Antiviral Therapy (AVT): 20
188. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response
189. Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy
190. Rapid Reversal of Parenteral-Nutrition-Associated Cirrhosis Following Isolated Intestinal Transplantation
191. Treatment of hepatitis C in the potential liver transplant recipient
192. Improving Advance Care Planning in Outpatients With Decompensated Cirrhosis: A Pilot Study
193. Erythropoietin administration expands regulatory T cells in patients with autoimmune hepatitis
194. COVID‐19 Aftershocks on Alcohol‐Associated Liver Disease: An Early Cross‐Sectional Report From the U.S. Epicenter
195. A protocol for the management of hyponatremia peri‐liver transplant reduces post‐transplant neurological complications
196. Liver Injury in Hospitalized Patients with COVID‐19 Correlates with Hyper Inflammatory Response and Elevated IL‐6
197. Splenic T 1ρ as a noninvasive biomarker for portal hypertension
198. Modelling and numerical simulation of the spread of a dense and high-temperature fluid
199. Modélisation et simulation numérique de l'étalement d'un fluide dense et à haute température
200. THU-201 - Digital pathology quantification of cirrhosis severity continuum in human HCV liver biopsies and its correspondence with Laennec and Beijing stages
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.